IBDEI2SS ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44616,1,3,0)
 ;;=3^ADLS Training Ea 15Min
 ;;^UTILITY(U,$J,358.3,44617,0)
 ;;=96105^^166^2215^2^^^^1
 ;;^UTILITY(U,$J,358.3,44617,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,44617,1,2,0)
 ;;=2^96105
 ;;^UTILITY(U,$J,358.3,44617,1,3,0)
 ;;=3^Aphasia Assessment w/ Interp & Rpt,Per Hr
 ;;^UTILITY(U,$J,358.3,44618,0)
 ;;=90901^^166^2215^7^^^^1
 ;;^UTILITY(U,$J,358.3,44618,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,44618,1,2,0)
 ;;=2^90901
 ;;^UTILITY(U,$J,358.3,44618,1,3,0)
 ;;=3^Biofeedback Training Any Method
 ;;^UTILITY(U,$J,358.3,44619,0)
 ;;=97750^^166^2215^10^^^^1
 ;;^UTILITY(U,$J,358.3,44619,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,44619,1,2,0)
 ;;=2^97750
 ;;^UTILITY(U,$J,358.3,44619,1,3,0)
 ;;=3^Extremity Performance Testing Ea 15Min
 ;;^UTILITY(U,$J,358.3,44620,0)
 ;;=97165^^166^2215^12^^^^1
 ;;^UTILITY(U,$J,358.3,44620,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,44620,1,2,0)
 ;;=2^97165
 ;;^UTILITY(U,$J,358.3,44620,1,3,0)
 ;;=3^OT Evaluation,Low Complexity
 ;;^UTILITY(U,$J,358.3,44621,0)
 ;;=97166^^166^2215^13^^^^1
 ;;^UTILITY(U,$J,358.3,44621,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,44621,1,2,0)
 ;;=2^97166
 ;;^UTILITY(U,$J,358.3,44621,1,3,0)
 ;;=3^OT Evaluation,Moderate Complexity
 ;;^UTILITY(U,$J,358.3,44622,0)
 ;;=97167^^166^2215^11^^^^1
 ;;^UTILITY(U,$J,358.3,44622,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,44622,1,2,0)
 ;;=2^97167
 ;;^UTILITY(U,$J,358.3,44622,1,3,0)
 ;;=3^OT Evaluation,High Complexity
 ;;^UTILITY(U,$J,358.3,44623,0)
 ;;=97168^^166^2215^14^^^^1
 ;;^UTILITY(U,$J,358.3,44623,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,44623,1,2,0)
 ;;=2^97168
 ;;^UTILITY(U,$J,358.3,44623,1,3,0)
 ;;=3^OT Re-Evaluation
 ;;^UTILITY(U,$J,358.3,44624,0)
 ;;=97161^^166^2215^16^^^^1
 ;;^UTILITY(U,$J,358.3,44624,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,44624,1,2,0)
 ;;=2^97161
 ;;^UTILITY(U,$J,358.3,44624,1,3,0)
 ;;=3^PT Evaluation,Low Complexity
 ;;^UTILITY(U,$J,358.3,44625,0)
 ;;=97162^^166^2215^17^^^^1
 ;;^UTILITY(U,$J,358.3,44625,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,44625,1,2,0)
 ;;=2^97162
 ;;^UTILITY(U,$J,358.3,44625,1,3,0)
 ;;=3^PT Evaluation,Moderate Complexity
 ;;^UTILITY(U,$J,358.3,44626,0)
 ;;=97163^^166^2215^15^^^^1
 ;;^UTILITY(U,$J,358.3,44626,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,44626,1,2,0)
 ;;=2^97163
 ;;^UTILITY(U,$J,358.3,44626,1,3,0)
 ;;=3^PT Evaluation,High Complexity
 ;;^UTILITY(U,$J,358.3,44627,0)
 ;;=97164^^166^2215^18^^^^1
 ;;^UTILITY(U,$J,358.3,44627,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,44627,1,2,0)
 ;;=2^97164
 ;;^UTILITY(U,$J,358.3,44627,1,3,0)
 ;;=3^PT Re-Evaluation
 ;;^UTILITY(U,$J,358.3,44628,0)
 ;;=96112^^166^2215^8^^^^1
 ;;^UTILITY(U,$J,358.3,44628,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,44628,1,2,0)
 ;;=2^96112
 ;;^UTILITY(U,$J,358.3,44628,1,3,0)
 ;;=3^Developmental Testing w/ Int & Rpt,1st Hr
 ;;^UTILITY(U,$J,358.3,44629,0)
 ;;=96113^^166^2215^9^^^^1
 ;;^UTILITY(U,$J,358.3,44629,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,44629,1,2,0)
 ;;=2^96113
 ;;^UTILITY(U,$J,358.3,44629,1,3,0)
 ;;=3^Developmental Testing w/ Int & Rpt,Ea Addl 30 min
 ;;^UTILITY(U,$J,358.3,44630,0)
 ;;=97172^^166^2215^6^^^^1
 ;;^UTILITY(U,$J,358.3,44630,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,44630,1,2,0)
 ;;=2^97172
 ;;^UTILITY(U,$J,358.3,44630,1,3,0)
 ;;=3^Athletic Trn Re-Eval Plan,Ea 20 min
 ;;^UTILITY(U,$J,358.3,44631,0)
 ;;=97171^^166^2215^3^^^^1
